Brought to you by 
Ascletis to sell Roche’s HCV medicine danoprevir in greater China
23 Jul 2019
Executive Summary
Oncology and infectious disease spec pharma Ascletis Inc. has received rights in China, Taiwan, Hong Kong, and Macau to develop, manufacture, and market Roche’s direct-acting antiviral agent danoprevir, which is in Phase II for hepatitis C virus (HCV). Ascletis will be calling the compound by the lab code ASC08.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ascletis to sell Roche’s HCV medicine danoprevir in greater China
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice